• Abbott posted 2Q26 net earnings of $928 million, down 47.8%, with diluted EPS of $0.53 versus $1.31 adjusted.
• Net sales climbed 13% to $12.59 billion, while comparable sales growth was 4.8%.
• Operating earnings fell 17.5% to $1.69 billion as operating costs and expenses rose 19.9% to $10.9 billion.
• Full-year adjusted diluted EPS guidance was raised to $5.45-$5.60; comparable sales growth outlook was reaffirmed at 6.5%-7.5%.
• Management flagged accelerating momentum into 2H; CE Mark secured for Libre Duo, FDA filing completed for Amulet 360, TECTONIC IVL U.S. trial enrollment finished.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160730PR_NEWS_USPR_____CG05490) on July 16, 2026, and is solely responsible for the information contained therein.